http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 17 Jun 2026 08:01:22 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Gossamer+Bio+exchange+offer+closes+with+%2418.9M+in+notes+remaining/26657102.html <p>Gossamer Bio, Inc. (NASDAQ: GOSS) announced the final results of its exchange offer for its existing 5.00% Convertible Senior Notes due 2027, with $18,948,000 in aggregate principal amount of those notes remaining outstanding after the offer's conclusion.</p><p>As of 5:00 p.m. New York time on June 2, 2026, $181,052,000 in aggregate principal amount of the existing notes had been validly tendered. The company and required supporting noteholders agreed to lower the minimum tender condition from 98% to 90.5% of the aggregate principal amount. Early settlement occurred on June 4, 2026.</p><p>No additional notes were tendered by the final deadline of 5:00 p.m. http://www.streetinsider.com/Corporate+News/Gossamer+Bio+exchange+offer+closes+with+%2418.9M+in+notes+remaining/26657102.html Wed, 17 Jun 2026 08:01:22 -0400 GOSS http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Jun+17/26657126.html si-local-file:///var/storage/secattach/20260617/26657126.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Jun+17/26657126.html Wed, 17 Jun 2026 08:01:00 -0400 GOSS O.38966322 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Jun+17/26657126.html si-local-file:///var/storage/secattach/20260617/26657126.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Jun+17/26657126.html Wed, 17 Jun 2026 08:01:00 -0400 GOSS O.38966322 http://www.streetinsider.com/Press+Releases/Gossamer+Bio%2C+Inc.+Announces+Final+Tender+Results+for+Exchange+Offer+and+Consent+Solicitation+with+Respect+to+Existing+Convertible+Notes/26657042.html <p> SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the final tender results of its previously announced exchange offer (the “Exchange Offer”) to exchange any and all of its 5.00% Convertible Senior Notes due 2027 (the “Existing Convertible Notes”) for a pro rata portion of (i) up to $72.0 million in aggregate principal amount of its new 7.50% Convertible Senior Secured First Lien Notes http://www.streetinsider.com/Press+Releases/Gossamer+Bio%2C+Inc.+Announces+Final+Tender+Results+for+Exchange+Offer+and+Consent+Solicitation+with+Respect+to+Existing+Convertible+Notes/26657042.html Wed, 17 Jun 2026 08:00:00 -0400 A.40028331 GOSS O.08192455 O.38966322 http://www.streetinsider.com/Press+Releases/Gossamer+Bio%2C+Inc.+Announces+Final+Tender+Results+for+Exchange+Offer+and+Consent+Solicitation+with+Respect+to+Existing+Convertible+Notes/26657042.html <p> SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the final tender results of its previously announced exchange offer (the “Exchange Offer”) to exchange any and all of its 5.00% Convertible Senior Notes due 2027 (the “Existing Convertible Notes”) for a pro rata portion of (i) up to $72.0 million in aggregate principal amount of its new 7.50% Convertible Senior Secured First Lien Notes http://www.streetinsider.com/Press+Releases/Gossamer+Bio%2C+Inc.+Announces+Final+Tender+Results+for+Exchange+Offer+and+Consent+Solicitation+with+Respect+to+Existing+Convertible+Notes/26657042.html Wed, 17 Jun 2026 08:00:00 -0400 A.40028331 GOSS O.08192455 O.38966322 http://www.streetinsider.com/Press+Releases/Gossamer+Bio%2C+Inc.+Announces+Final+Tender+Results+for+Exchange+Offer+and+Consent+Solicitation+with+Respect+to+Existing+Convertible+Notes/26657042.html <p> SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the final tender results of its previously announced exchange offer (the “Exchange Offer”) to exchange any and all of its 5.00% Convertible Senior Notes due 2027 (the “Existing Convertible Notes”) for a pro rata portion of (i) up to $72.0 million in aggregate principal amount of its new 7.50% Convertible Senior Secured First Lien Notes http://www.streetinsider.com/Press+Releases/Gossamer+Bio%2C+Inc.+Announces+Final+Tender+Results+for+Exchange+Offer+and+Consent+Solicitation+with+Respect+to+Existing+Convertible+Notes/26657042.html Wed, 17 Jun 2026 08:00:00 -0400 A.40028331 GOSS O.08192455 O.38966322 http://www.streetinsider.com/Press+Releases/Gossamer+Bio%2C+Inc.+Announces+Final+Tender+Results+for+Exchange+Offer+and+Consent+Solicitation+with+Respect+to+Existing+Convertible+Notes/26657042.html <p> SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the final tender results of its previously announced exchange offer (the “Exchange Offer”) to exchange any and all of its 5.00% Convertible Senior Notes due 2027 (the “Existing Convertible Notes”) for a pro rata portion of (i) up to $72.0 million in aggregate principal amount of its new 7.50% Convertible Senior Secured First Lien Notes http://www.streetinsider.com/Press+Releases/Gossamer+Bio%2C+Inc.+Announces+Final+Tender+Results+for+Exchange+Offer+and+Consent+Solicitation+with+Respect+to+Existing+Convertible+Notes/26657042.html Wed, 17 Jun 2026 08:00:00 -0400 A.40028331 GOSS O.08192455 O.38966322 http://www.streetinsider.com/Business+Wire/Gossamer+Bio%2C+Inc.+Announces+Final+Tender+Results+for+Exchange+Offer+and+Consent+Solicitation+with+Respect+to+Existing+Convertible+Notes/26657042.html <p> SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the final tender results of its previously announced exchange offer (the “Exchange Offer”) to exchange any and all of its 5.00% Convertible Senior Notes due 2027 (the “Existing Convertible Notes”) for a pro rata portion of (i) up to $72.0 million in aggregate principal amount of its new 7.50% Convertible Senior Secured First Lien Notes http://www.streetinsider.com/Business+Wire/Gossamer+Bio%2C+Inc.+Announces+Final+Tender+Results+for+Exchange+Offer+and+Consent+Solicitation+with+Respect+to+Existing+Convertible+Notes/26657042.html Wed, 17 Jun 2026 08:00:00 -0400 A.40028331 GOSS O.08192455 O.38966322 http://www.streetinsider.com/Business+Wire/Gossamer+Bio%2C+Inc.+Announces+Final+Tender+Results+for+Exchange+Offer+and+Consent+Solicitation+with+Respect+to+Existing+Convertible+Notes/26657042.html <p> SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the final tender results of its previously announced exchange offer (the “Exchange Offer”) to exchange any and all of its 5.00% Convertible Senior Notes due 2027 (the “Existing Convertible Notes”) for a pro rata portion of (i) up to $72.0 million in aggregate principal amount of its new 7.50% Convertible Senior Secured First Lien Notes http://www.streetinsider.com/Business+Wire/Gossamer+Bio%2C+Inc.+Announces+Final+Tender+Results+for+Exchange+Offer+and+Consent+Solicitation+with+Respect+to+Existing+Convertible+Notes/26657042.html Wed, 17 Jun 2026 08:00:00 -0400 A.40028331 GOSS O.08192455 O.38966322 http://www.streetinsider.com/Business+Wire/Gossamer+Bio%2C+Inc.+Announces+Final+Tender+Results+for+Exchange+Offer+and+Consent+Solicitation+with+Respect+to+Existing+Convertible+Notes/26657042.html <p> SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the final tender results of its previously announced exchange offer (the “Exchange Offer”) to exchange any and all of its 5.00% Convertible Senior Notes due 2027 (the “Existing Convertible Notes”) for a pro rata portion of (i) up to $72.0 million in aggregate principal amount of its new 7.50% Convertible Senior Secured First Lien Notes http://www.streetinsider.com/Business+Wire/Gossamer+Bio%2C+Inc.+Announces+Final+Tender+Results+for+Exchange+Offer+and+Consent+Solicitation+with+Respect+to+Existing+Convertible+Notes/26657042.html Wed, 17 Jun 2026 08:00:00 -0400 A.40028331 GOSS O.08192455 O.38966322 http://www.streetinsider.com/Business+Wire/Gossamer+Bio%2C+Inc.+Announces+Final+Tender+Results+for+Exchange+Offer+and+Consent+Solicitation+with+Respect+to+Existing+Convertible+Notes/26657042.html <p> SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the final tender results of its previously announced exchange offer (the “Exchange Offer”) to exchange any and all of its 5.00% Convertible Senior Notes due 2027 (the “Existing Convertible Notes”) for a pro rata portion of (i) up to $72.0 million in aggregate principal amount of its new 7.50% Convertible Senior Secured First Lien Notes http://www.streetinsider.com/Business+Wire/Gossamer+Bio%2C+Inc.+Announces+Final+Tender+Results+for+Exchange+Offer+and+Consent+Solicitation+with+Respect+to+Existing+Convertible+Notes/26657042.html Wed, 17 Jun 2026 08:00:00 -0400 A.40028331 GOSS O.08192455 O.38966322 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13D++Gossamer+Bio%2C+Inc.+++++++++++++++++++++Filed+by%3A+D.+E.+SHAW+%26amp%3B+CO%2C+L.P./26637299.html si-local-file:///var/storage/secattach/20260611/26637299.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13D++Gossamer+Bio%2C+Inc.+++++++++++++++++++++Filed+by%3A+D.+E.+SHAW+%26amp%3B+CO%2C+L.P./26637299.html Thu, 11 Jun 2026 21:13:00 -0400 GOSS O.38966322 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13D++Gossamer+Bio%2C+Inc.+++++++++++++++++++++Filed+by%3A+D.+E.+SHAW+%26amp%3B+CO%2C+L.P./26637299.html si-local-file:///var/storage/secattach/20260611/26637299.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13D++Gossamer+Bio%2C+Inc.+++++++++++++++++++++Filed+by%3A+D.+E.+SHAW+%26amp%3B+CO%2C+L.P./26637299.html Thu, 11 Jun 2026 21:13:00 -0400 GOSS O.38966322 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Gossamer+Bio%2C+Inc.+++++++++++++++++++++Filed+by%3A+DeepCurrents+Investment+Group+LLC/26637229.html si-local-file:///var/storage/secattach/20260611/26637229.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Gossamer+Bio%2C+Inc.+++++++++++++++++++++Filed+by%3A+DeepCurrents+Investment+Group+LLC/26637229.html Thu, 11 Jun 2026 20:11:00 -0400 GOSS O.38966322 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Gossamer+Bio%2C+Inc.+++++++++++++++++++++Filed+by%3A+DeepCurrents+Investment+Group+LLC/26637229.html si-local-file:///var/storage/secattach/20260611/26637229.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Gossamer+Bio%2C+Inc.+++++++++++++++++++++Filed+by%3A+DeepCurrents+Investment+Group+LLC/26637229.html Thu, 11 Jun 2026 20:11:00 -0400 GOSS O.38966322 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Gossamer+Bio%2C+Inc.+++++++++++++++++++++Filed+by%3A+683+Capital+Management%2C+LLC/26636564.html si-local-file:///var/storage/secattach/20260611/26636564.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Gossamer+Bio%2C+Inc.+++++++++++++++++++++Filed+by%3A+683+Capital+Management%2C+LLC/26636564.html Thu, 11 Jun 2026 16:55:00 -0400 GOSS O.38966322 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Gossamer+Bio%2C+Inc.+++++++++++++++++++++Filed+by%3A+683+Capital+Management%2C+LLC/26636564.html si-local-file:///var/storage/secattach/20260611/26636564.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Gossamer+Bio%2C+Inc.+++++++++++++++++++++Filed+by%3A+683+Capital+Management%2C+LLC/26636564.html Thu, 11 Jun 2026 16:55:00 -0400 GOSS O.38966322 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Gossamer+Bio%2C+Inc.++++++++For%3A+Jul+14/26623935.html si-local-file:///var/storage/secattach/20260609/26623935.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Gossamer+Bio%2C+Inc.++++++++For%3A+Jul+14/26623935.html Tue, 09 Jun 2026 16:19:00 -0400 GOSS O.38966322 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Gossamer+Bio%2C+Inc.++++++++For%3A+Jul+14/26623935.html si-local-file:///var/storage/secattach/20260609/26623935.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Gossamer+Bio%2C+Inc.++++++++For%3A+Jul+14/26623935.html Tue, 09 Jun 2026 16:19:00 -0400 GOSS O.38966322 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Gossamer+Bio%2C+Inc.+++++++++++++++++++++Filed+by%3A+Context+Capital+Management%2C+LLC/26621048.html si-local-file:///var/storage/secattach/20260609/26621048.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Gossamer+Bio%2C+Inc.+++++++++++++++++++++Filed+by%3A+Context+Capital+Management%2C+LLC/26621048.html Tue, 09 Jun 2026 08:44:00 -0400 GOSS O.38966322 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Gossamer+Bio%2C+Inc.+++++++++++++++++++++Filed+by%3A+Context+Capital+Management%2C+LLC/26621048.html si-local-file:///var/storage/secattach/20260609/26621048.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Gossamer+Bio%2C+Inc.+++++++++++++++++++++Filed+by%3A+Context+Capital+Management%2C+LLC/26621048.html Tue, 09 Jun 2026 08:44:00 -0400 GOSS O.38966322 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Jun+04++Filed+by%3A+Quisel+John+D/26612409.html si-local-file:///var/storage/secattach/20260605/26612409.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Jun+04++Filed+by%3A+Quisel+John+D/26612409.html Fri, 05 Jun 2026 17:46:00 -0400 GOSS O.38966322 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Jun+04++Filed+by%3A+Quisel+John+D/26612409.html si-local-file:///var/storage/secattach/20260605/26612409.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Jun+04++Filed+by%3A+Quisel+John+D/26612409.html Fri, 05 Jun 2026 17:46:00 -0400 GOSS O.38966322 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Jun+04++Filed+by%3A+Drynan+Skye/26611556.html si-local-file:///var/storage/secattach/20260605/26611556.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Jun+04++Filed+by%3A+Drynan+Skye/26611556.html Fri, 05 Jun 2026 16:31:00 -0400 GOSS O.38966322 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Jun+04++Filed+by%3A+Drynan+Skye/26611556.html si-local-file:///var/storage/secattach/20260605/26611556.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Jun+04++Filed+by%3A+Drynan+Skye/26611556.html Fri, 05 Jun 2026 16:31:00 -0400 GOSS O.38966322